



OPAL BIOSCIENCES LIMITED

ABN 97 605 631 963

Level 4,

100 Albert Road,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: [www.opalbiosciences.com](http://www.opalbiosciences.com)

## Announcement

### Company Update and EOFY 2023 Information

**Melbourne, 4 August 2023:** Opal Biosciences Ltd (“Opal”) is pleased to provide the following update.

- On 21 June Opal announced its proposed merger with specialist company, Formulytica Pty Ltd (“Formulytica”).
- On 18 July 2023 Opal announced it had been awarded an Investment Attraction Fund grant of \$5m by the Government of Western Australia. The grant will support establishment of a manufacturing facility in Perth to develop and formulate the materials required for use in clinical trials particularly small batch manufacture of sterile injectables and vaccines.
- On 31 July 2023 Opal lodged an MRFF National Critical Infrastructure grant application requesting \$5m to support the Perth facility and a program to manufacture personalised medicines.

### EOFY Share Price information\*

The EOFY 2023 share price information is as follows being the pricing of the last capital raise:

Opal Biosciences Ltd ordinary shares = \$0.075 (7.5 cents)

\*The Company does not provide any advice regarding valuation, and shareholders are encouraged to seek their own professional advice in relation to valuation of their shares.

### Shareholder Information maintained by Vistra (previously Leydin Freyer).

Leydin Freyer has now become part of Vistra (<https://www.leydinfreyer.com.au/about/vistra-update/>). Vistra maintains Opal’s share register. Shareholders can update their contact details and email addresses by contacting [jphillips@opalbiosciences.com](mailto:jphillips@opalbiosciences.com).

- ENDS -

### Further information

Julie Phillips, Managing Director, Opal Biosciences Ltd

Phone +61 3 9692 7222

Email [jphillips@opalbiosciences.com](mailto:jphillips@opalbiosciences.com)